Benzinga · Aug 19, 2026
SL
NASDAQ · SLS
SELLAS Life Sciences Group, Inc.
Healthcare · Biotechnology
$15.21
Down-$1.43 (-9.40%)
Updated Aug 28, 2026, 5:44 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 211.34M
- P/E ratio
- -7.53
- Dividend yield
- 0.00%
- 52-week range
- $1.39 – $15.88
- Volume
- 12.1M
- Avg. volume
- 4.07M
Price performance
SLS price history
1M range · 21 trading sessions · Daily adjusted prices
SLS closed at $15.21 after 21 trading sessions, up 47.81% for the selected period.
- Last close
- $15.21
- Period change
- +47.81%
- Period low
- $10.01
- Period high
- $15.46
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $14.078 | $15.56 | $13.9157 | $15.21 | 12.1M |
| Aug 26, 2026 | $13.815 | $13.915 | $13.41 | $13.73 | 4.59M |
| Aug 25, 2026 | $14.56 | $15.39 | $13.91 | $14.09 | 8.21M |
| Aug 24, 2026 | $15.475 | $15.48 | $13.91 | $14.325 | 8.82M |
| Aug 21, 2026 | $13.69 | $15.67 | $13.26 | $15.46 | 15.24M |
| Aug 20, 2026 | $13.84 | $14.4364 | $13.01 | $13.40 | 7.82M |
| Aug 19, 2026 | $13.46 | $14.29 | $13.00 | $13.85 | 9.12M |
| Aug 18, 2026 | $12.66 | $13.48 | $12.53 | $13.10 | 4.97M |
| Aug 17, 2026 | $12.78 | $13.25 | $12.39 | $13.00 | 5.43M |
| Aug 14, 2026 | $12.40 | $13.00 | $12.1818 | $12.78 | 4.41M |
| Aug 13, 2026 | $11.70 | $12.585 | $11.40 | $12.36 | 5.67M |
| Aug 12, 2026 | $11.92 | $12.45 | $11.50 | $11.77 | 7.8M |
| Aug 11, 2026 | $11.27 | $11.39 | $10.85 | $11.05 | 4.72M |
| Aug 10, 2026 | $11.95 | $12.0021 | $10.91 | $11.04 | 5.24M |
| Aug 7, 2026 | $11.95 | $12.21 | $11.61 | $12.01 | 5.12M |
| Aug 6, 2026 | $11.62 | $12.18 | $11.59 | $11.70 | 3.77M |
| Aug 5, 2026 | $11.80 | $12.06 | $11.39 | $11.86 | 5.76M |
| Aug 4, 2026 | $11.40 | $11.94 | $11.06 | $11.81 | 5.09M |
| Aug 3, 2026 | $10.00 | $11.43 | $9.80 | $11.22 | 6.97M |
| Jul 31, 2026 | $10.37 | $10.54 | $9.87 | $10.01 | 5.04M |
| Jul 30, 2026 | $9.93 | $10.351 | $9.76 | $10.29 | 4.32M |
Latest SLS news
The latest Smart Investors Daily articles mentioning SLS.
Stock researchCompany · Overview
SLS research
Overview
Company profile and research snapshot.
Company profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Maxim Group | Buy | — |
| Nov 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2022 | Alliance Global Partners | Buy | — |
| Jun 28, 2022 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 13, 2026
This One Data Readout Could Make Or Break Sellas Life Sciences Group
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. Click here to read this SLS stock update.
Benzinga · Aug 11, 2026
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share
SeekingAlpha · Aug 6, 2026
Stock Picks From Seeking Alpha's July 2026 New Analysts
Discover Seeking Alphaâs July spotlight on top new analysts and highestâconviction stock ideasâfrom Strong Sell to Strong Buy.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
